Show articles from
Eight weeks of hepatitis C (HCV) treatment with a novel three-drug
combination was not as good as an older combination of two drugs
delivered for 12 weeks, a researcher reported here.
Use of of an investigational immunotherapy called GS-4774 in combination
with tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB)
patients was safe and well tolerated in a phase II study, investigators
Ninety-nine percent of hepatitis C patients with five genotypes achieve cure
Sofosbuvir-velpatasvir appears optimal when paired with ribavirin
High compliance rates, sustained virologic response with investigational combination
In patients infected with both HIV and hepatitis C (HCV), direct-acting
antiviral agents produced high rates of 12-week HCV viral eradication,
particularly in patients without decompensated cirrhosis, a Spanish
investigator reported here.
Extension studies suggest investigational drug has efficacy up to 5 years
BOSTON -- For patients with advanced liver disease owing to hepatitis C (HCV), treatment with direct-acting antiviral agents did not increase the risk of hepatocellular carcinoma, a researcher said here.
An investigational combination of antiviral agents was almost
universally successful in curing hepatitis C (HCV) patients with severe
kidney disease, a researcher said here.
Pegylated interferon alfa-2a is effective in children and teens with
chronic hepatitis B (HBV), an investigator reported here, and is also
BOSTON -- In the era of direct-acting agents against hepatitis C (HCV), the treatment of many patients can be effectively referred to nonspecialist care without loss of efficacy, a researcher reported here.
In the past 16 years, Veterans' Administration doctors have cured more
than 57,000 people with hepatitis C (HCV) -- about half of them in
2015, a researcher said here.